Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133614 | 0.92 | DRD3 (0.52) | MAPTPOLBALDH1A1TSHRHRH3 | |
| SCHEMBL6134554 | 0.87 | HRH3 (0.51) | HRH3DRD3DRD2 | |
| SCHEMBL5787289 | 0.85 | MAPT (0.59) | MAPTPOLBALDH1A1TSHRHTR7 | |
| SCHEMBL6134734 | 0.85 | HRH3 (0.51) | MAPTALDH1A1TSHRHRH3DRD3 | |
| SCHEMBL6134614 | 0.84 | DRD3 (0.47) | MAPTPOLBALDH1A1TSHRHRH3 | |
| SCHEMBL6134968 | 0.82 | MAOB (0.47) | ALDH1A1HRH3DRD2HTT | |
| SCHEMBL6132700 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1TSHRSMN1; SMN2HDAC3 | |
| SCHEMBL6132706 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1TSHRSMN1; SMN2HDAC3 | |
| SCHEMBL6134389 | 0.81 | DRD3 (0.51) | HRH3DRD3DRD2 | |
| SCHEMBL6132756 | 0.81 | ALDH1A1 (0.45) | MAPTALDH1A1TSHRSMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | MAPT 1629/4885POLB 1754/4885ALDH1A1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.